ProCE Banner Activity

Slideset: Pharmacotherapies for Psychiatric Disorders: What Does the Future Hold

Slideset Download

This presentation on pharmacotherapies for psychiatric disorders will review new and novel pharmacologics, including those currently in the clinic, in the pipeline, and treatments of the future. Covered topics include: depression, schizophrenia, bipolar, and ADHD.

Released: December 08, 2021

Share

Faculty

Greg W. Mattingly

Greg W. Mattingly, MD

Associate Clinical Professor
Department of Psychiatry
Washington University School of Medicine
President
St. Charles Psychiatry Associates
St. Louis, Missouri

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Independent Educational Activity

Faculty Disclosure

Primary Author

Greg W. Mattingly, MD

Associate Clinical Professor
Department of Psychiatry
Washington University School of Medicine
President
St. Charles Psychiatry Associates
St. Louis, Missouri

Greg W. Mattingly, MD: consultant/advisor/speaker: AbbVie, Acadia, Alkermes, Axsome, Corium, Eisai, Ironshore, Intracellular, Janssen, Lumos Labs, Lundbeck, MedPoint, Neos, Neurocrine, Noven, Otsuka, Redax, Roche, Rhodes, Sage, Skye Therapeutics, Sunovion, Supernus, Takeda, Teva, Trispharma; researcher: AbbVie, Acadia, Alkermes, Akilli, Axsome, Boehringer Ingelheim, Corium, Emalex, Idorsida, Janssen, Karuna, Lumos Labs, Medgenics, NLS-1 Pharma AG, Otsuka, Redax, Relmada, Roche, Sage, Sirtsei, Sunovion, Supernus, Takeda, Teva.